Latest

Fresh coverage on markets, the economy, and the forces moving money.

Jun 4, 2026

Markets

Private Payrolls Add 122,000 Jobs in May, But Fed Holds Rates at 6.75%

Private employers added 122,000 jobs in May, the strongest hiring month since January 2025, with gains spread across eight of ten sectors.

2 min read

Jun 4, 2026

Economy

May Jobs Report Shows 122,000 Gains as Fed Grapples With Inflation

Workers' wages are lagging price growth, with average hourly earnings up 3.6% annually while prices jumped 3.8%, compressing household purchasing power.

2 min read

May 29, 2026

Company Deep Dive

How TSMC Achieved 59.9% Gross Margin as AI Nodes Eclipse Smartphones

TSMC's commitment to a pure-play foundry model has concentrated market power, allowing it to claim 69.9% of the global foundry market and command a 59.9% gross margin in 2025.

4 min read

May 29, 2026

Company Deep Dive

Nvidia overtakes Apple as largest customer at TSMC where top 10 accounts yield 76%

TSMC's dedicated foundry model pools rival chip designers to amortize massive fab costs, driving gross margins to 66.2% by renting out the world's scarcest leading-edge capacity.

4 min read

May 29, 2026

Company Deep Dive

TSMC Grows Gross Margin to 59.9% as Fabless Chip Designers Rely on Its Nodes

TSMC leverages its neutral foundry model to turn product design risks into a manufacturing annuity, yielding a 59.9% gross margin in 2025.

5 min read

May 28, 2026

Sector Transformation

Federal drug pricing policies force GLP-1 margin compression and volume dependency

Federal price caps limiting GLP-1 treatments to $350 monthly force pharmaceutical companies to trade premium margins for mass-market volume.

5 min read

May 28, 2026

Sector Transformation

GLP-1 duopoly shifts healthcare capital from chronic care to upfront pharmacology

GLP-1 receptor agonists convert a diffuse obesity cost pool into a concentrated pharmaceutical revenue stream controlled by a highly constrained manufacturing duopoly.

7 min read

May 28, 2026

Sector Transformation

GLP-1 mass market demand collides with specialty drug pricing

The transition of obesity into a pharmacologically treated chronic condition forces an immediate collision between mass-market demand and specialty-drug pricing.

7 min read

May 28, 2026

Sector Transformation

Novo Nordisk and Eli Lilly manufacturing bottlenecks constrain the GLP-1 market

Novo Nordisk and Eli Lilly control the GLP-1 market through a physical ceiling on sterile fill-finish capacity, forcing competitors out and driving billions into vertical integration.

8 min read

May 28, 2026

Sector Transformation

GLP-1 adoption strains employer health plans and restructures pharmacy benefit manager rebates

Eli Lilly and Novo Nordisk navigate a $200 billion incretin market through divergent capital allocation strategies prioritizing domestic manufacturing and acquisitive capacity integration.

6 min read

Load more